The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

(Alliance News) - AstraZeneca PLC on Wednesday said its drug camizestrant significantly delayed disease progression in a phase III trial for advanced hormone receptor-positive breast cancer, ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report) has been given a consensus rating of “Hold” by the five research ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy ...

Cyclin B3, on the other hand, plays an important role in meiosis, another type of cell division. It is responsible for ensuring that meiotic division takes place correctly and that a healthy egg ...

Colon cancer continues to be one of the leading causes of cancer-related deaths worldwide, with poor dietary habits ...

However, the precise mechanism by which these processes are concertedly gated remains unknown. Our study demonstrates that cyclin-dependent kinase 5 (Cdk5) activity is modulated by light and regulates ...

In two studies, we tested whether the docking site on cyclin B – a type of pocket contributes to the correct sequence of events and, if so, what effects it has. By making targeted changes to ...

"We are excited to outline a clear path for Zentalis to bring azenosertib to patients with Cyclin E1+ PROC,” said Ingmar Bruns, M.D., Chief Medical Officer. “In a patient population with a ...

Drug addiction is a major therapeutic challenge, as little is known about the changes in neural function that occur during its development. DNA microarray analysis has revealed a new component in ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across ...